Biblio

Found 12 results
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is Polman, C H  [Clear All Filters]
2011
Bosma LV, Kragt JJ, Knol DL, Polman CH, Uitdehaag BM. Clinical scales in progressive MS: predicting long-term disability. Mult Scler [Internet]. 2011. Available from: http://www.hubmed.org/display.cgi?uids=21868487
Kempen JC, de Groot V, Knol DL, Polman CH, Lankhorst GJ, Beckerman H. Community walking can be assessed using a 10-metre timed walk test. Mult Scler [Internet]. 2011;17:980-990. Available from: http://www.hubmed.org/display.cgi?uids=21622593
Hulst HE, Schoonheim MM, Roosendaal SD, Popescu V, Schweren LJ, van der Werf YD, Visser LH, Polman CH, Barkhof F, Geurts JJ, et al. Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. Hum Brain Mapp [Internet]. 2011. Available from: http://www.hubmed.org/display.cgi?uids=21898674
Schoonheim MM, Geurts JJ, Landi D, Douw L, van der Meer ML, Vrenken H, Polman CH, Barkhof F, Stam CJ. Functional connectivity changes in multiple sclerosis patients: A graph analytical study of MEG resting state data. Hum Brain Mapp [Internet]. 2011. Available from: http://www.hubmed.org/display.cgi?uids=21954106
Lee LF, Axtell R, Tu GH, Logronio K, Dilley J, Yu J, Rickert M, Han B, Evering W, Walker MG, et al. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci Transl Med [Internet]. 2011;3:93-93. Available from: http://www.hubmed.org/display.cgi?uids=21795588
Seewann A, Vrenken H, Kooi EJ, van der Valk P, Knol DL, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ. Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Mult Scler [Internet]. 2011;17:1202-1210. Available from: http://www.hubmed.org/display.cgi?uids=21561955
Bush WS, McCauley JL, De Jager PL, Dudek SM, Hafler DA, Gibson RA, Matthews PM, Kappos L, Naegelin Y, Polman CH, et al. A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes Immun [Internet]. 2011;12:335-340. Available from: http://www.hubmed.org/display.cgi?uids=21346779
Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol [Internet]. 2011;10:1026-1034. Available from: http://www.hubmed.org/display.cgi?uids=22014437
Sombekke MH, van der Voort LF, Kragt JJ, Nielsen JM, Guzel H, Visser A, Oudejans CB, Crusius JB, Peña AS, Vrenken H, et al. Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis. Mult Scler [Internet]. 2011;17:922-930. Available from: http://www.hubmed.org/display.cgi?uids=21543551
Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler [Internet]. 2011;17:970-979. Available from: http://www.hubmed.org/display.cgi?uids=21421809
2009
Tenser RB, Polman CH. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology [Internet]. 2009;72:1191-1192. Available from: http://www.hubmed.org/display.cgi?uids=19332703
2007
van Winsen LM, Hooper-van Veen T, van Rossum EF, Koper JW, Barkhof F, Polman CH, Uitdehaag BM. Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS. J Neuroimmunol [Internet]. 2007;186:150-155. Available from: http://www.hubmed.org/display.cgi?uids=17395275